Investors

Faron Pharmaceuticals (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on creating innovative cancer treatments that leverage the patient’s own immune system.

Share price (helsinki)

Share price (london)

Faron presented the full phase 2 interim data from BEXMAB trial at the 66th American Society of Hematology (ASH) Annual Meeting on 10 December in San Diego, USA. See more in the accompanying webinar, where Juho Jalkanen, CEO of Faron, and Faron’s Chief Medical officer Petri Bono presents the results.

On 22 October 2024, Faron hosted a Capital Markets Day at the company’s facilities in Turku and on-line. In the event, Juho Jalkanen, CEO of Faron, discussed Faron’s strategy and key focus areas for the coming years. Dr. Kontro shared updated survival data from the ongoing BEXMAB Phase I/II trial and Mr. Hughes presented the results of recently conducted market research in MDS. Dr. Bono provided Faron’s development plan for solid tumors, discussed bexmarilimab’s further potential as first-in-class immune-oncological treatment and introduced the Company’s new Scientific Advisory Board (SAB).

Please review the latest Faron Pharmaceuticals investor presentation in the accompanying presentation. The presentation covers Faron’s strategy, development pipeline, key strengths, and financials.